Compare WEX & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEX | DNTH |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.9B |
| IPO Year | 2004 | 2018 |
| Metric | WEX | DNTH |
|---|---|---|
| Price | $197.77 | $77.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 17 |
| Target Price | ★ $195.36 | $140.80 |
| AVG Volume (30 Days) | 461.0K | ★ 865.0K |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.93 | N/A |
| EPS | ★ 5.33 | N/A |
| Revenue | ★ $2,660,800,000.00 | $2,036,000.00 |
| Revenue This Year | $8.92 | N/A |
| Revenue Next Year | $1.57 | N/A |
| P/E Ratio | $37.18 | ★ N/A |
| Revenue Growth | ★ 1.24 | N/A |
| 52 Week Low | $125.29 | $32.28 |
| 52 Week High | $203.99 | $117.88 |
| Indicator | WEX | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 69.70 | 33.18 |
| Support Level | $183.52 | $75.50 |
| Resistance Level | $203.97 | $91.36 |
| Average True Range (ATR) | 4.68 | 4.05 |
| MACD | 3.16 | 0.51 |
| Stochastic Oscillator | 96.34 | 40.47 |
WEX Inc is a commerce platform that provides seamlessly embedded, personalized payments solutions. The company operates three business segments: Mobility, Benefits, and Corporate Payments. Mobility segment, the top segment by revenue, provides fleet vehicle payment solutions, transaction processing, and information management services for commercial and government fleets. The Corporate Payments segment offers business-to-business payment processing and transaction monitoring services. The Benefits segment generates revenue from healthcare payment products and its consumer-directed software platform. Its prime end market is the United States of America.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.